EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-03-03 05:54:01
Psoriasis has a complex collection of risk factors, such as genetics, lifestyle choices, and exposure to certain environmental conditions. There were approximately 36.5 million prevalent cases of psoriasis across all the US, France, Germany, Italy, Spain, UK, Japan, China, and India in 2012. By 2022, epidemiologists forecast that this figure will reach approximately 40.93 million prevalent cases, following a 12.1% increase based on projected population growth - prevalence proportions are expected to remain constant.
Psoriasis is an immune-mediated chronic dermatological disorder characterized by redness and irritation. The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world. The age-standardized prevalence of psoriasis varies among different countries, from as low as 0.03% in Japan to as high as 1.84% in Germany. These regional differences may be attributable to variations in environmental factors such as the weather, as well as genetic factors, and differences in data collection across different countries.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy, and similar regional differences have been reported in Spain, with psoriasis more common among the residents of central Spain, who experience colder and drier weather than individuals in the northern and southern regions.
Ethnicity may also play a part - studies have shown that Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.
Psoriasis is an autoimmune disorder, so family history plays an important role in the development of the disease. Approximately 40% of psoriasis patients have first-degree relatives with the disease. Since psoriasis is categorized as an immune-mediated inflammatory disorder (IMFD), sufferers are also at an increased risk of developing other, more severe IMFDs, such as rheumatoid arthritis and Crohns disease.
Psoriasis patients are also at risk of developing psoriatic arthritis, which is a progressive, deforming, and debilitating disease and the most common comorbidity associated with psoriasis. However, lifestyle choices, and certain diseases and medications can affect the condition. Smoking increases the risk of developing psoriasis, and increases the severity of the disease. In addition, it has been noted that psoriasis is a common disease among obese patients, although the relationship between the two disorders remains unclear. Obesity also predisposes individuals to inverse or flexural psoriasis, which occurs in the folds of the skin. Various medications, such as lithium, anti-malarial agents, betablocking agents, and non-steroidal anti-inflammatory drugs (NSAIDs), are also considered as possible risk factors, though there is insubstantial evidence to prove this as yet.
The disease can be controlled with medication, but a cure has not yet been found. Psoriasis is often associated with unsightly lesions, scales, and inflammation, which can affect an individuals self-esteem, leading nearly half of all psoriasis patients to report elevated stress levels, depression, and thoughts of suicide. Stress can trigger pathological processes, exacerbating many dermatological conditions, particularly psoriasis. Psoriasis patients suffering from these anxieties can also limit their social interactions and abuse alcohol and tobacco, further worsening their condition.
- The Psoriasis EpiCast Report provides an overview of the risk factors and global trends of psoriasis in the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India).
- It includes a 10-year epidemiology forecast of the prevalent cases of psoriasis segmented by sex and age (by five-year increments, beginning at age 15 years and ending at =85 years) in the 9MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global psoriasis market.
- Quantify patient populations in the global psoriasis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for psoriasis therapeutics in each of the markets covered.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.